Anderberg 2000.

Study characteristics
Methods	Design: parallel Duration: 16 weeks Assessment: baseline and post‐intervention Country: Sweden
Participants	Pain condition: fibromyalgia Population: women with fibromyalgia Minimum pain duration: no Inclusion criteria Diagnosis of fibromyalgia fulfilling the ACR criteria (1990) Exclusion criteria Patients with any severe heart diseases, such as angina pectoris or post‐heart infarction, or other severe heart diseases, as well as brain infarction, suicidal thoughts or who were seriously depressed (in need of immediate psychiatric care) Patients taking major or minor tranquillisers, major antidepressants or strong analgesics Total participants randomised: 40 Age in years (mean, SD): 48.6 (7.5) Gender: 40/40 were female Pain duration: 11.9 (7.0) years average duration of fibromyalgia
Interventions	Citalopram 30‐40 mg/ day Flexibly dosed Titrated from 10/20 mg to 30/40 mg in 5 mg doses every 5 days Placebo Inert Matched dosing schedule
Outcomes	AE Withdrawal
Missing data methods	ITT but no method reported
Funding source	The study was supported by grants from H. Lundbeck AB, the Söderström Königska Foundation, the Swedish Association of Physicians, the Märta and Nicke Nasvell Foundation, the Swedish Health Insurance System, the Uppsala County Council and ‘Förenade Liv’ Mutual Group Life Insurance Company, Stockholm, Sweden and the Swedish Medical Research Council (21X‐9523)
Conflicts of interest	NR
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information given
Allocation concealment (selection bias)	Low risk	Randomisation was made at a separate agency, and the investigator had a coded list. Included patients were given consecutive code numbers.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No information given regarding appearance of placebo
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not enough information given
Incomplete outcome data (attrition bias) All outcomes	High risk	Unequal attrition, states ITT but no method given Attrition: Total: 5/40 (12.5%) Placebo: 1/19 (5.26%) Citalopram 30‐40 mg: 4/21 (19.1%)
Selective reporting (reporting bias)	Low risk	No protocol or trial registration found
Other bias	Low risk	No other sources of bias were identified.